🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
North China Pharmaceutical Company.Ltd (SHA:600812)
China flag China · Delayed Price · Currency is CNY
4.230
-0.160 (-3.64%)
Nov 20, 2026, 3:00 PM CST

SHA:600812 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
7,6629,1389,79810,07010,44910,304
Other Revenue
103.99103.9971.7650.3251.1980.2
7,7669,2429,87010,12010,50010,385
Revenue Growth
-20.70%-6.36%-2.48%-3.62%1.11%-9.64%
Cost of Revenue
5,4986,3636,7326,9077,0636,691
Gross Profit
2,2682,8783,1383,2133,4373,694
Selling, General & Admin
1,3451,7802,0102,2682,4242,796
Research & Development
353.18339.77336.15294.2215.17151.93
Other Operating Expenses
81.8387.4190.82104.23117.57123.33
Operating Expenses
1,8022,2512,4792,6772,8023,094
Operating Income
466.6627.16658.87536.44634.8600.11
Interest Expense
-316.22-361.55-458.7-501.9-599.39-642.69
Interest & Investment Income
108.0686.4471.4274.5284.17126.62
Currency Exchange Gain (Loss)
-4.96-4.9617.5711.4923.31-8.32
Other Non Operating Income (Expenses)
-32.44-5.298.92-11.35-748.96-13.91
EBT Excluding Unusual Items
221.04341.81298.08109.2-606.0761.82
Impairment of Goodwill
---3.34---
Gain (Loss) on Sale of Assets
0.880.830.440.760.213.4
Asset Writedown
-22.65-0.76-1.4-0.05--
Legal Settlements
-1.72-1.72-0.5-0.49-0.78-1.14
Other Unusual Items
21.9217.2516.5549.1241.5670.84
Pretax Income
219.48357.41309.83158.54-565.07134.91
Income Tax Expense
72.6999.9694.87109.15113.7199.52
Earnings From Continuing Operations
146.79257.45214.9749.39-678.7835.38
Minority Interest in Earnings
-57.35-74.4-87.97-44.5-10.45-16.65
Net Income
89.44183.06126.994.89-689.2318.73
Net Income to Common
89.44183.06126.994.89-689.2318.73
Net Income Growth
-51.13%44.15%2496.79%---80.76%
Shares Outstanding (Basic)
1,6991,7111,7161,6301,7151,702
Shares Outstanding (Diluted)
1,6991,7111,7161,6301,7151,702
Shares Change
-1.62%-0.31%5.27%-4.92%0.70%4.96%
EPS (Basic)
0.050.110.070.00-0.400.01
EPS (Diluted)
0.050.110.070.00-0.400.01
EPS Growth
-50.33%44.59%2366.67%---81.67%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
696.11634.53445.35401.23454.81502.75
Free Cash Flow Per Share
0.410.370.260.250.270.29
Dividend Per Share
0.0350.0350.0300.010-0.060
Dividend Growth
16.67%16.67%200.00%--100.00%
Gross Margin
29.20%31.15%31.79%31.75%32.73%35.57%
Operating Margin
6.01%6.79%6.68%5.30%6.05%5.78%
Profit Margin
1.15%1.98%1.29%0.05%-6.56%0.18%
Free Cash Flow Margin
8.96%6.87%4.51%3.96%4.33%4.84%
EBITDA
1,4281,5171,4521,2751,3471,224
EBITDA Margin
18.39%16.41%14.71%12.60%12.83%11.79%
D&A For EBITDA
961.66889.37792.99739.01712624
EBIT
466.6627.16658.87536.44634.8600.11
EBIT Margin
6.01%6.79%6.68%5.30%6.05%5.78%
Effective Tax Rate
33.12%27.97%30.62%68.85%-73.77%
Revenue as Reported
7,7669,2429,87010,12010,50010,385
Advertising Expenses
-109.62119.86133.01127.89185.19